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Phosphodiesterase-5 (PDE5) inhibitors
have shown a beneficial effect in a vari-
ety of clinical conditions, such as benign
prostate hyperplasia, pulmonary arte-
rial hypertension, female sexual arousal
disorder, overactive bladder, and incon-
tinence, Raynaud’s disease, heart failure
and stroke among others (Sandner et al.,
2007). Three PDE5 inhibitors, sildenafil
(Viagra™), tadalafil (Cialis™) and varde-
nafil (Levitra™) are clinically approved
and are widely used for the treatment of
erectile dysfunction. A retrospective anal-
ysis determined that men treated with
PDE5 for ED had less chance of having
prostate cancer. This population of men
had significantly lower documented diag-
nosis of elevated prostate-specific antigen
and higher percentage of benign pro-
static hyperplasia compared to men not
treated with PDE-5 inhibitors (Chavez
et al., 2013). Emerging evidence indicates
that PDE5 inhibitors are multi-targeting
agents and have promising results in the
treatment of variety of tumors. Here
we propose the possibility of repur-
posing of PDE5 inhibitors for adjuvant
chemotherapy.
PDE5 contributes to the regulation of
intracellular cyclic GMP (cGMP) pools
(see Figure 1) that have been shown to
be decreased along with protein kinase-G
(PKG), a downstream effector of cGMP,
in variety of different tumors such as
breast cancer, colon cancer and human
oral squamous cell carcinoma (hOSCC)
(Spoto et al., 2003; Zhu and Strada, 2007;
Di et al., 2010). PDE5 hydrolyzes the
3′, 5′-phosphodiester bond in the sec-
ond messenger molecule cGMP to bio-
logically inactive 5′-GMP. There is an
incomplete understanding of how PDE5
inhibitors act in cancer, yet there are
reports of increased apoptosis in different
tumor cell types following treatment with
PDE5 inhibitors. Possible mechanisms of
these anticancer effects via PDE5 inhibi-
tion mediated caspase-dependent apop-
tosis and cell growth arrest may be
linked to concomitant increases in regu-
lation of downstream pathways through
increased cGMP-PKG levels and sub-
sequent effects on, (1) activation of
c-Jun NH2-terminal kinase (JNK), espe-
cially JNK1 pathways via phosphoryla-
tion of mitogen-activated protein kinase
kinase kinase 1 (MEKK1) (Bender and
Beavo, 2006), (2) decreasedWnt/β-catenin
expression and down-regulation of cyclin
D1 (Thompson et al., 2000; Li et al., 2002;
Tinsley et al., 2011), (3) inhibition of
extracellular-signal regulated kinases 1/2
(ERK1/2) and alterations in the regula-
tion of p42/p44 mitogen activated-protein
kinase (MAPK) and p21 pathways (Hou
et al., 2006; Das et al., 2008). Increased
PDE5 expression was shown to play a
role in tumorigenesis in variety of cancers,
such as non-small cell lung cancer, uri-
nary bladder cancer, metastatic breast can-
cer and development of hOSCC (Piazza
et al., 2001; Pusztai et al., 2003; Whitehead
et al., 2003). Thus, it is hypothesized
that inhibiting PDE5 activity may pro-
duce antineoplastic actions. There is a
small amount of supporting data. Indeed,
PDE5 inhibitors, sildenafil and vardenafil
induced caspase-dependent apoptosis of
B-cell chronic lymphocytic leukemia cells
(Sarfati et al., 2003), whereas cytotoxic
and growth suppressive effects in var-
ious breast cancer, prostate, and colon
cells were seen with non-specific PDE5
inhibitors sulindac sulfone and its analogs
(Thompson et al., 2000; Piazza et al.,
2001; Whitehead et al., 2003; Tinsley
et al., 2011). Interestingly, PDE5 inhibitors
were shown to alter the tumor microen-
vironment by augmenting endogenous
antitumor immunity by reducingmyeloid-
derived suppressor cell function (Serafini
et al., 2006).
The accumulating body of evidence
suggests that PDE5 inhibitors could inter-
fere with the efflux functions of the ABC
transporters, thus sensitizing cancer cells
toward cytotoxic agents that are substrates
of ABC transporters (Ding et al., 2011;
Shi et al., 2011; Chen et al., 2012) (see
Figure 1). For example, cGMP is a sub-
strate of ABCC4 and ABCC5 transporters
that are involved in reducing its intracellu-
lar concentrations. Sildenafil reverses this
phenomenon through a dual action, first it
inhibits PDE5, and secondly it could block
the transport function of ABCC4 and
ABCC5, thus increasing the intracellular
cGMP concentrations (Jedlitschky et al.,
2000; Chen et al., 2001). More recently
our group reported that specific PDE5
inhibitors could block the function of ABC
transporters at clinically achievable con-
centrations (Ding et al., 2011; Shi et al.,
2011; Chen et al., 2012). We showed that
sildenafil could block the efflux functions
of ABCB1 and ABCG2 transporters in can-
cer cells, and thus, significantly reversed
the MDR-mediated efflux of substrate
anticancer drugs, such as mitoxantrone,
paclitaxel, and vinca alkaloids (Shi et al.,
2011). Other PDE5 inhibitors, vardenafil
and tadalafil were also examined for their
effect on ABC transporter-mediated efflux
in cancer cells. It was found that vardenafil
in a concentration-dependent manner,
significantly potentiated the cytotoxicity
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FIGURE 1 | Schematic model of PDE5 inhibitors mechanism as
chemoadjuvants: Proposed model is shown (A) as how tumor cells
can efflux cGMP and variety of anticancer drugs that are substrate
of ABCB1, ABCG2, ABCC4, ABCC5, and ABCC10 and so survive in
the absence of PDE5 inhibitors. (B) Probable mechanism by which the
PDE5 inhibitors such as sildenafil, vardenafil and tadalafil produces
apoptotic activity is shown, which may be due to (1) inhibition of PDE5
activity, thus increasing cGMP-PKG activation, which leads to activation of
series of signaling events including phosphorylation of β-catenin and/or
MEKK1/SEK1/JNK1 signaling pathways that eventually results in apoptosis
cascade, and/or (2) inhibition of efflux function of ABCC4, ABCC5,
ABCC10, ABCB1, and ABCG2 drug transporters and thus increase the
sensitivity of other chemotherapeutic agents that are substrates of these
transporters. ABCXX, refers to ABCB1, ABCG2, ABCC4, ABCC5, or
ABCC10; cGMP, cyclic guanosine monophosphate; ERK1/2, extra-cellular
regulated kinases 1/2; MAPK, mitogen-activated protein kinase; PKG,
Protein kinase G; PDE5, Phosphodiesterase type 5; ROS, Reactive
oxygen species.
of anticancer agents that are substrates
of ABCB1, but not that of ABCC1 or
ABCG2 transporters and this effect was
significantly greater than that of tadalafil
(Ding et al., 2011). Furthermore, silde-
nafil and vardenafil enhanced the activ-
ity of paclitaxel, docetaxel and vinblastine
in the ABCC10-transfected HEK293 cells
(Chen et al., 2012). Recently, we found
that sildenafil significantly enhanced the
sensitivity of specific anticancer drugs in
different tumor cell lines and in ABCB1-
and ABCG2-bearing MDR mouse models
(unpublished data). These novel functions
of PDE5 inhibitors might explain why in
brain tumor models, doxorubicin and her-
ceptin transport efficacy across the blood-
brain tumor barrier was enhanced by the
addition of sildenafil and vardenafil (Black
et al., 2008). Combination chemother-
apy with PDE5 inhibitors was shown to
produce reactive oxygen species and led
to apoptosis that proved to be beneficial
in treatment of broad range of cancers.
For example, enhanced tumor suppres-
sion and apoptotic activity was seen with
a sulindac-docetaxel combination in non-
small cell lung cancer orthotopic lung
tumor model (Whitehead et al., 2003),
and with a sulindac-capecitabine combi-
nation in breast cancer (Pusztai et al.,
2003), and more recently, with the combi-
nation of sildenafil-doxorubicin in in vivo
models of prostate cancer (Das et al.,
2010). We suspect that these combination
therapies may have produced enhanced
anticancer activity partly due to inhibi-
tion of specific ABC transporters, which
otherwise reduced intracellular concen-
tration of substrate anticancer agents,
but this hypothesis needs to be tested.
Furthermore, since the PDE5 inhibitors
are substrates of multiple ABC trans-
porters, their individual or overlapping
roles (Tiwari et al., 2013) in PDE5 dispo-
sition is an open area of research.
In summary, there is evidence that
suggests that PDE5 inhibitors may have
an anticancer action either by increas-
ing cGMP-PKG and coupled downstream
events or by their ability to inhibit ABC
transporter—mediated s efflux of anti-
cancer drugs. The safety, high tolerability,
and wide availability of PDE5 inhibitors
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have made this class of drug an attractive
tool to investigate their role in cancer
chemotherapy. Since a detailed under-
standing of PDE5 inhibitors as anticancer
adjuvants is limited, further studies are
warranted to characterize their mecha-
nisms and establish their role.
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